Semaglutide cuts heart-rhythm and cardiovascular risks in type 2 diabetes

Semaglutide, a GLP-1 receptor agonist, has already shown promise for managing high blood sugar and reducing cardiovascular outcomes in type 2 diabetes. What has remained uncertain is whether it also affects heart-rhythm disturbances such as atrial fibrillation, along with major cardiovascular events and microvascular complications like retinopathy. Heart-rhythm problems matter because they are common companions to type 2 diabetes and carry serious downstream risks. This review set out to settle whether the drug moves those outcomes at all, and in which direction.

The authors ran a systematic review and meta-analysis, searching PubMed, Embase and Cochrane databases for randomised controlled trials reported up to November 2024. They pooled 30 eligible RCTs covering 32490 patients with type 2 diabetes and estimated overall relative risks with 95% confidence intervals using a random-effects model. Subgroup analyses split the results by administration type, treatment comparison and treatment duration. A meta-regression examined whether baseline patient characteristics explained variation in retinopathy complications across trials.

Compared with controls, semaglutide significantly reduced atrial fibrillation (relative risk 0.73), complete atrioventricular block (relative risk 0.22), death from cardiovascular causes (relative risk 0.76) and revascularisation (relative risk 0.68). Subgroup analyses showed that long-term treatment reduced the risk of atrial fibrillation, supraventricular tachycardia and complete atrioventricular block, suggesting the arrhythmia benefit builds with duration. For retinopathy complications, the meta-regression found that heterogeneity across trials was not explained by baseline patient characteristics. Confidence intervals for atrial fibrillation and cardiovascular death sat close to the boundary of no effect, so the size of those benefits remains uncertain.

Semaglutide's cardiovascular benefits were already reasonably established; this analysis extends the picture into arrhythmic territory, where the evidence had been unclear. The finding that longer treatment yields greater rhythm benefits adds a duration dimension to the existing story. Open questions remain: the microvascular picture, particularly retinopathy, is not resolved here, and the mechanisms behind the arrhythmia reduction are not addressed in this analysis. Whether any of this applies to people taking the drug without type 2 diabetes is also untested by these trials.

If you or someone close to you lives with type 2 diabetes, this is a reason to think of semaglutide's benefits as broader than blood sugar and weight: the pooled trial evidence now points to fewer rhythm disturbances, fewer cardiovascular deaths and fewer artery-opening procedures. It is also a reason to understand that duration appears to matter, since the rhythm benefits were clearer with long-term treatment. This is population-level trial evidence in a specific patient group, so it describes averages rather than any individual's outcome, and treatment decisions sit with a clinician.